Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization

Tetra Discovery Partners and Shionogi & Co., Ltd. today announced they have entered into a strategic collaboration for the clinical development and commercialization of BPN14770, Tetra’s selective phosphodiesterase-4D (PDE4D) allosteric inhibitor, for the treatment of Fragile X Syndrome, Alzheimer’s disease and other indications marked by cognitive and memory deficits.

Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent

Tetra Discovery Partners today announced that the U.S. Patent and Trademark Office has issued a third patent covering the company’s selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds. The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia. “This new…

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome, the most common genetic form of autism. A selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype, BPN14770 has shown the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model.

FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile X Syndrome

Tetra Discovery Partners today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for BPN14770 for the treatment of Fragile X Syndrome. BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype. Research conducted collaboratively with the FRAXA Research Foundation has shown BPN14770 to improve the quality…

Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome

Tetra Discovery Partners Inc. (Tetra) today announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770, a novel, selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) enzyme, which research suggests may be useful in the treatment of Fragile X Syndrome and possibly other autism spectrum disorders.…

New Preclinical Research Suggests Utility of Tetra Discovery Partners’ BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome

Daily treatment with BPN14770 in a mouse Fragile X model showed reduced hyperarousal, improved social interactions, and improved natural behaviors, as well as changes in neuronal dendrite structure Benefit persisted two weeks after washout of the drug BPN14770 has demonstrated human safety and tolerability in Phase 1 clinical safety study Research results published online this…

Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition

Preclinical, PET imaging, and Phase 1 human clinical evidence supporting the ability of Tetra Discovery Partners’ drug candidate, BPN14770, to improve memory formation and provide cognitive benefit was the subject of an oral presentation on Saturday at the 10th Clinical Trials in Alzheimer’s Disease Meeting held November 1‐4, 2017 in Boston, MA. BPN14770 is a…

Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770

BPN14770 shown safe and orally bioavailable in single and multiple dose studies Cognitive benefit on working memory seen at lower doses in healthy elderly subjects in multiple dose trial Results support planned initiation of Phase 2 study in Alzheimer’s disease in mid- 2017 Tetra Discovery Partners today announced positive results from two Phase 1 studies…

Tetra Discovery Partners Raises $10 Million through Series A Financing and Two National Institutes of Health Grants

Tetra Discovery Partners today announced that it has closed a $5 million Series A Venture Financing. The financing was co-led by the Apjohn Group and Grand Angels, with the participation of previous investors as well as Dolby Family Ventures, the Alzheimer’s Drug Discovery Foundation, and other private investors. With conversion of two debt rounds, the…

Research from University of Miami and Tetra Discovery Shows Potential of Novel Drug to Improve Memory after Traumatic Brain Injury

Treating rats with an experimental drug at three months following a traumatic brain injury (TBI) improves their learning memory ability, as reported in a new study published online today in the July edition of The Journal of Neuroscience. The drug, a selective phosphodiesterase 4 subtype inhibitor (PDE4B), is currently under development by Tetra Discovery Partners,…